The most consequential feature of Venus Medtech’s Venus-PowerX is not the valve itself but what happens when a physician changes their mind mid-procedure: the device can be fully retrieved even after 100% deployment, a capability the company has protected with enough engineering specificity (wire-controlled release, self-adaptive skirt, three radiopaque markers) that no currently marketed self-expanding TAVR platform replicates it in that exact configuration. With enrollment now closed in the PREVAILS study, a prospective, multicenter, single-arm confirmatory trial in severe aortic stenosis patients, Venus Medtech is positioning for simultaneous regulatory submissions to China’s NMPA and for CE marking in Europe under the EU Medical Device Regulation 2017/745, the stricter framework that replaced earlier directives in May 2021 and that has lengthened review cycles for structural heart devices across the board.
The trial design carries real strategic weight. Single-arm studies with objective performance criteria are the standard architecture for TAVR pivotals, but they live and die on endpoint selection and comparator benchmarks. PREVAILS will generate the clinical package Venus Medtech needs, and the Latin American commercial footprint matters here more than it might seem: Argentina and Chile are already producing real-world evidence on the retrieval mechanism under actual procedural conditions, not just bench testing. That data does not substitute for the pivotal readout, but it lets the regulatory dossier arrive with an outcomes narrative already attached. The dry-valve construction with anti-calcification treatment also addresses one of the documented durability concerns that has shadowed tissue-based TAVR valves over long follow-up, which is relevant as indications trend younger.
The commercial context is not forgiving. Edwards Lifesciences generated $4.5 billion in TAVR sales in 2025 and holds over 60% of the global market, with Medtronic occupying most of the remaining share. Displacing either company in Europe or China requires more than a retrievability claim; it requires a procedural safety signal compelling enough to change implanter behavior. PREVAILS will need to demonstrate that the full-retrieval mechanism translates into measurably fewer paravalvular leak corrections, positioning failures, or reinterventions, not just that retrieval is mechanically possible.
The single number to track when PREVAILS data read out is the rate of device repositioning or retrieval actually used during procedures. If operators are deploying the feature at a clinically meaningful frequency and achieving acceptable outcomes, Venus Medtech has a genuine differentiation story. If retrieval remains a theoretical backstop almost never invoked, the valve competes on conventional metrics where incumbents hold structural advantages.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
